Literature DB >> 15586230

Differential susceptibility of metastatic and primary oral cancer cells to TRAIL-induced apoptosis.

Nadarajah Vigneswaran1, Jean Wu, Nagathihalli Nagaraj, Karen Adler-Storthz, Wolfgang Zacharias.   

Abstract

TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) preferentially induces apoptosis of cancer cells without toxicity in normal cells. TRAIL plays an important role in host immune surveillance against tumor metastasis. Cathepsin B (CB) is a mediator of apoptosis whose activity is regulated by its inhibitors, known as cystatins. We examined the TRAIL-mediated cytotoxicity rates of clonally-related primary and metastatic oral cancer (OC) cells and correlated them with the expression levels of TRAIL receptors, cathepsin B and cystatins A, B, C and M. Two pairs of primary (686Tu and 101A) and metastatic (686Ln and 101B) OC cell lines were treated with various concentrations (5 to 1000 ng/ml) of recombinant human TRAIL protein for 14 h, and cell viability and apoptotic rate were determined. In both pairs of cell lines, primary OC cells revealed greater susceptibility to TRAIL than their metastatic counterparts. The protein synthesis inhibitor cycloheximide markedly increased the TRAIL sensitivity of these cell lines, whereas the CB-specific chemical inhibitor CA-074 markedly reduced the sensitivity of primary OC cells to TRAIL. DNA laddering and M30 CytoDEATH immunodetection assays confirmed that TRAIL-induced OC cell death is an apoptotic process. Expression levels of TRAIL death (DR4 and DR5) and decoy (DcR1 and DcR2) receptors were not different between primary and metastatic OC cells. However, expression levels of cystatins were higher in metastatic OC cells than in their respective primary cells, whereas CB levels remain unchanged. Cathepsin B is a mediator of TRAIL-induced apoptosis in OC cells. Elevated levels of cystatins in metastatic OC cells may cause their greater resistance to TRAIL-induced apoptosis. Our data suggest that high expression of cystatins in OC cells may confer a metastatic phenotype by enhancing their resistance to TRAIL.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15586230

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  12 in total

1.  Cathepsin B mediates TRAIL-induced apoptosis in oral cancer cells.

Authors:  Nagathihalli S Nagaraj; Nadarajah Vigneswaran; Wolfgang Zacharias
Journal:  J Cancer Res Clin Oncol       Date:  2005-12-16       Impact factor: 4.553

2.  Hypoxia-induced autophagic response is associated with aggressive phenotype and elevated incidence of metastasis in orthotopic immunocompetent murine models of head and neck squamous cell carcinomas (HNSCC).

Authors:  Nadarajah Vigneswaran; Jean Wu; Anren Song; Ananth Annapragada; Wolfgang Zacharias
Journal:  Exp Mol Pathol       Date:  2011-01-12       Impact factor: 3.362

3.  Hypoxia inhibits TRAIL-induced tumor cell apoptosis: involvement of lysosomal cathepsins.

Authors:  Nagathihalli S Nagaraj; Nadarajah Vigneswaran; Wolfgang Zacharias
Journal:  Apoptosis       Date:  2007-01       Impact factor: 4.677

4.  Peroxiredoxin 6 interferes with TRAIL-induced death-inducing signaling complex formation by binding to death effector domain caspase.

Authors:  H Choi; J-W Chang; Y-K Jung
Journal:  Cell Death Differ       Date:  2010-09-10       Impact factor: 15.828

Review 5.  Metastasis suppressor function of tumor necrosis factor-related apoptosis-inducing ligand-R in mice: implications for TRAIL-based therapy in humans?

Authors:  Anne Grosse-Wilde; Christopher J Kemp
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

6.  TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development.

Authors:  Anne Grosse-Wilde; Oksana Voloshanenko; S Lawrence Bailey; Gary M Longton; Uta Schaefer; Andreea I Csernok; Günther Schütz; Erich F Greiner; Christopher J Kemp; Henning Walczak
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

7.  PSMA-specific theranostic nanoplex for combination of TRAIL gene and 5-FC prodrug therapy of prostate cancer.

Authors:  Zhihang Chen; Marie-France Penet; Balaji Krishnamachary; Sangeeta R Banerjee; Martin G Pomper; Zaver M Bhujwalla
Journal:  Biomaterials       Date:  2015-12-02       Impact factor: 12.479

8.  Gene expressions and copy numbers associated with metastatic phenotypes of uterine cervical cancer.

Authors:  Heidi Lyng; Runar S Brøvig; Debbie H Svendsrud; Ruth Holm; Olav Kaalhus; Kjetil Knutstad; Halldis Oksefjell; Kolbein Sundfør; Gunnar B Kristensen; Trond Stokke
Journal:  BMC Genomics       Date:  2006-10-20       Impact factor: 3.969

9.  Hypoxia-mediated apoptosis in oral carcinoma cells occurs via two independent pathways.

Authors:  Nagathihalli S Nagarajah; Nadarajah Vigneswaran; Wolfgang Zacharias
Journal:  Mol Cancer       Date:  2004-12-21       Impact factor: 27.401

10.  Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression.

Authors:  Nadarajah Vigneswaran; Darryl C Baucum; Jean Wu; Yahuan Lou; Jerry Bouquot; Susan Muller; Wolfgang Zacharias
Journal:  BMC Cancer       Date:  2007-06-25       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.